Lupin has been granted the Food and Drug Administration’s approval for its triamcinolone acetonide ointment 0.1%.The product is a generic version of Mylan Pharmaceuticals’ triamcinolone acetonide ointment 0.1%.It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.Triamcinolone acetonide ointment 0.1% had a market value of approximately $25.7 million, according to June 2018 IQVIA data.